Actively Recruiting
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Led by Mayo Clinic · Updated on 2026-03-12
324
Participants Needed
3
Research Sites
157 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
E
Elephas Biosciences Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
CONDITIONS
Official Title
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older
- Diagnosed with or suspected of Stage IV/metastatic or recurrent malignancies including NSCLC, cutaneous malignancy excluding uveal melanoma, esophageal, cervical, endometrial, mismatch repair deficient colorectal, high tumor mutation burden or microsatellite instability high solid tumors, liver cancer
- Diagnosed with or suspected of Stage III or IV clear cell renal cell carcinoma, urothelial carcinoma of bladder, or other solid tumors eligible for immune checkpoint inhibitor therapy
- Patients receiving neoadjuvant checkpoint inhibitor therapy for resectable early stage triple negative breast cancer or non-small cell lung cancer
- Measurable disease present for locally advanced or metastatic patients (excluding lesions in previously irradiated areas or measurable only by physical exam)
- Treatment-na�ve at biopsy if newly diagnosed or suspected cancer
- No anti-cancer treatment for at least 2-4 weeks prior to biopsy if progressed to metastatic stage I-III
- Eastern Cooperative Oncology Group Performance Status 0, 1, or 2
- Negative pregnancy test within 7 days prior to enrollment for persons of childbearing potential
- Female participants must not be pregnant or breastfeeding and use appropriate contraception
- Willing and able to undergo additional biopsy during standard care or separate research biopsy
- Patients with known secondary cancer diagnosis eligible if it does not interfere with treatment for primary diagnosis
- Provide written informed consent
You will not qualify if you...
- Pregnant women
- Severe co-morbid illnesses or other severe diseases interfering with study participation or biopsy safety
- Immunocompromised patients and HIV-positive patients currently on antiretroviral therapy
- Uncontrolled illnesses including active infection or psychiatric/social conditions limiting compliance
- Participation in or planned enrollment in a blinded cancer therapeutic treatment trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Mayo Clinic in Arizona
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224
Actively Recruiting
3
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here